← All trials
NCT06565195
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2024
- Primary completion
- May 5, 2029
- Completion date
- May 5, 2029
- First posted
- Aug 21, 2024
- Last posted
- Oct 18, 2024
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Prevail TherapeuticsLead sponsor
- Eli LillyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.